Literature DB >> 21203759

Cancer of the gastric cardia is rising in incidence in an Asian population and is associated with adverse outcome.

Chris Deans1, Matthew S W Yeo, Mu Yar Soe, Asim Shabbir, T K Ti, Jimmy B Y So.   

Abstract

BACKGROUND: Tumors arising from the esophagogastric junction (OGJ) are increasing in incidence in the west, but data from Asian populations are conflicting. Singapore has a mixed-Asian population with an international lifestyle. This study was designed to examine the changing trends in incidence of gastric cardia cancer (type III) within this population and to compare the clinicopathological characteristics and outcome of these tumors with gastric tumors.
METHODS: Trends in cancer incidence were obtained from the Singapore Cancer Registry. Clinicopathological data were prospectively collected from patients undergoing surgery for gastric cancer who presented to the National University Hospital between 2000 and 2005. Patients underwent surgery with or without (neo)adjuvant therapy. Survival duration was analyzed.
RESULTS: The incidence of cardia tumors has increased each decade since 1968 (1968-1982, 6.3%; 1983-1992, 7.6%; 1993-1997, 8.4%; 1998-2002, 9.1%; 2003-2007, 16.2%). Among the study population (n = 159) cardia tumors were associated with male sex (p < 0.01) and dysphagia (p < 0.01). Although R0 resection rates were similar, systemic recurrence rates were higher among patients with cardia cancer (p = 0.031) and survival was reduced compared with patients with non-cardia gastric cancer (median survival 26 vs. 69 months; p < 0.001). Cardia location of the tumor and metastatic lymph node ratio were identified as independent adverse prognostic indicators on multivariate analysis.
CONCLUSIONS: Similar to western societies, the incidence of proximal gastric cancer is increasing in Singapore. Cardia tumors are associated with poorer outcomes, suggesting that cardia cancer is a distinct disease from true gastric cancer requiring different management strategies to improve the outcome for these patients.

Entities:  

Mesh:

Year:  2011        PMID: 21203759     DOI: 10.1007/s00268-010-0935-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  27 in total

1.  Trends in reported adenocarcinomas of the oesophagus and gastric cardia in Japan.

Authors:  Martin J Blaser; Daizo Saito
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-02       Impact factor: 2.566

2.  Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach.

Authors:  Hiroaki Saito; Youji Fukumoto; Tomohiro Osaki; Kenji Fukuda; Shigeru Tatebe; Shunichi Tsujitani; Masahide Ikeguchi
Journal:  World J Surg       Date:  2006-10       Impact factor: 3.352

Review 3.  Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification.

Authors:  J Rüdiger Siewert; Marcus Feith; Hubert J Stein
Journal:  J Surg Oncol       Date:  2005-06-01       Impact factor: 3.454

Review 4.  Review article: Barrett's oesophagus and carcinoma in Japan.

Authors:  M Hongo
Journal:  Aliment Pharmacol Ther       Date:  2004-12       Impact factor: 8.171

5.  The prognosis of gastric cardia cancer after R0 resection.

Authors:  Ji Yeong An; Yong Hae Baik; Min Gew Choi; Jae Hyung Noh; Tae Sung Sohn; Jae Moon Bae; Sung Kim
Journal:  Am J Surg       Date:  2009-10-17       Impact factor: 2.565

6.  Pattern and surgical treatment of gastric cancer in Singapore.

Authors:  T K Ti
Journal:  Br J Surg       Date:  1993-07       Impact factor: 6.939

7.  A rising trend of gastric cardia cancer in Gansu Province of China.

Authors:  Yongning Zhou; Zhiyi Zhang; Zhenkun Zhang; Jing Wu; Denxian Ren; Xiang Yan; Qing Wang; Yuling Wang; Huizheng Wang; Jun Zhang; Xiaoling Zhu; Yongchen Yang; Chong Luo; Xian Guo; Chengwei Tang; Liang Qiao
Journal:  Cancer Lett       Date:  2008-05-22       Impact factor: 8.679

8.  Trends in incidence of oesophageal and stomach cancer subtypes in Europe.

Authors:  Jessie Steevens; Anita A M Botterweck; Miranda J M Dirx; Piet A van den Brandt; Leo J Schouten
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-06       Impact factor: 2.566

9.  Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan.

Authors:  Chika Kusano; Takuji Gotoda; Christopher J Khor; Hitoshi Katai; Hoichi Kato; Hirokazu Taniguchi; Tadakazu Shimoda
Journal:  J Gastroenterol Hepatol       Date:  2008-11       Impact factor: 4.029

10.  Generation and validation of a revised classification for oesophageal and junctional adenocarcinoma.

Authors:  C J Peters; R H Hardwick; S L Vowler; R C Fitzgerald
Journal:  Br J Surg       Date:  2009-07       Impact factor: 6.939

View more
  49 in total

Review 1.  Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction.

Authors:  Kei Hosoda; Keishi Yamashita; Natusya Katada; Masahiko Watanabe
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-08-01

2.  New observations regarding Helicobacter pylori and gastric cancer in Mongolia.

Authors:  Boldbaatar Gantuya; Dashdorj Bolor; Khasag Oyuntsetseg; Yansan Erdene-Ochir; Ruvjir Sanduijav; Duger Davaadorj; Tegshee Tserentogtokh; Dashdorj Azzaya; Tomohisa Uchida; Takeshi Matsuhisa; Yoshio Yamaoka
Journal:  Helicobacter       Date:  2018-06-08       Impact factor: 5.753

3.  Comparison of advanced adenocarcinomas of esophagogastric junction and distal stomach in Japanese patients.

Authors:  Akiko Kawano; Takako Eguchi Nakajima; Ichiro Oda; Nobukazu Hokamura; Satoru Iwasa; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Hirofumi Fujii; Yasuhiro Shimada
Journal:  Gastric Cancer       Date:  2013-02-24       Impact factor: 7.370

4.  Gastric cardia cancer: how much is it from fat?

Authors:  Preetika Sinh; Prateek Sharma
Journal:  Dig Dis Sci       Date:  2012-10       Impact factor: 3.199

5.  Superiority of laparoscopic proximal gastrectomy with hand-sewn esophagogastrostomy over total gastrectomy in improving postoperative body weight loss and quality of life.

Authors:  Tatsuto Nishigori; Hiroshi Okabe; Shigeru Tsunoda; Hisashi Shinohara; Kazutaka Obama; Hisahiro Hosogi; Shigeo Hisamori; Kikuko Miyazaki; Takeo Nakayama; Yoshiharu Sakai
Journal:  Surg Endosc       Date:  2017-01-11       Impact factor: 4.584

6.  Total vs proximal gastrectomy for adenocarcinoma of the upper third of the stomach: a propensity-score-matched analysis of a multicenter western experience (On behalf of the Italian Research Group for Gastric Cancer-GIRCG).

Authors:  Fausto Rosa; Giuseppe Quero; Claudio Fiorillo; Massimiliano Bissolati; Chiara Cipollari; Stefano Rausei; Damiano Chiari; Laura Ruspi; Giovanni de Manzoni; Guido Costamagna; Giovanni Battista Doglietto; Sergio Alfieri
Journal:  Gastric Cancer       Date:  2018-02-08       Impact factor: 7.370

7.  Microarray expression profile analysis of long non-coding RNAs of advanced stage human gastric cardia adenocarcinoma.

Authors:  Ying Wang; Xiaoshan Feng; Ruinuo Jia; Gang Liu; Mengxi Zhang; Daiming Fan; Shegan Gao
Journal:  Mol Genet Genomics       Date:  2014-01-12       Impact factor: 3.291

8.  Surgical and nutritional outcomes of laparoscopic proximal gastrectomy versus total gastrectomy: a meta-analysis.

Authors:  Toshiro Tanioka; Rawat Waratchanont; Ryosuke Fukuyo; Toshifumi Saito; Yuya Umebayashi; Emi Kanemoto; Kenta Kobayashi; Masatoshi Nakagawa; Mikito Inokuchi
Journal:  Surg Endosc       Date:  2020-01-13       Impact factor: 4.584

9.  Risk Factors and Prognostic Impact of Mediastinal Lymph Node Metastases in Patients with Esophagogastric Junction Cancer.

Authors:  Osamu Shiraishi; Takushi Yasuda; Hiroaki Kato; Mitsuru Iwama; Yoko Hiraki; Atsushi Yasuda; Masayuki Shinkai; Yutaka Kimura; Motohiro Imano
Journal:  Ann Surg Oncol       Date:  2020-05-14       Impact factor: 5.344

10.  Is gastroscopy for fecal immunochemical test positive patients worthwhile?

Authors:  Jing Yu Ng; Dedrick Kok Hong Chan; Ker Kan Tan
Journal:  Int J Colorectal Dis       Date:  2016-09-30       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.